Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Targeting NRF2 with quercetin in AML

Sara Olalla Saad • 8 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia

Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses nuclear factor-erythroid 2 related factor (NRF2), which is persistently activated in many human tumors, including acute myeloid leukemia (AML). She highlights how the natural polyphenolic flavonoid coumpound quercetin can target this protein and induce apoptosis, a potential therapetic strategy. She explains how her group are persuing this therapeutic avenue. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Sara Olalla Saad

Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
3:38
Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Sara Olalla Saad • 7 Dec 2019
FIBROMET preliminary results: metformin promising for primary MF
6:23
FIBROMET preliminary results: metformin promising for primary MF
Sara Olalla Saad • 8 Dec 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals